Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms

There is an urgent need for a vaccine to combat the hepatitis C virus (HCV) pandemic, and induction of broadly neutralizing monoclonal antibodies (bNAbs) against HCV is a major goal of vaccine development. Even within HCV genotype 1, no single bNAb effectively neutralizes all viral strains, so induc...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Proc Natl Acad Sci U S A
Päätekijät: Mankowski, Madeleine C., Kinchen, Valerie J., Wasilewski, Lisa N., Flyak, Andrew I., Ray, Stuart C., Crowe, James E., Bailey, Justin R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: National Academy of Sciences 2018
Aiheet:
PNAS Plus
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5776832/
https://ncbi.nlm.nih.gov/pubmed/29255018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1718441115
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia